Feasibility of Non-Anesthesiologist-Administered Propofol Sedation for Emergency Endoscopic Retrograde Cholangiopancreatography
Table 1
Baseline characteristics of 182 patients receiving ERCP with propofol sedation.
Total
Group A
Group B
value
Number of cases
182
149
33
Sex (male/female)
90/92
77/72
13/20
Age (mean ± SD)
75.4 ± 10.3
74.1 ± 10.3
82.2 ± 7.1
0.0019
Body mass index
22.7 ± 3.7
23.0 ± 3.8
21.2 ± 3.0
0.0060
Body weight (kg)
54.3 ± 13.1
55.3 ± 13.3
49.9 ± 11.0
0.0223
ASA-PS classification
I/II (%)
76 (41.8)
65 (43.6)
11 (33.3)
0.2781
III/IV (%)
106 (58.2)
84 (56.4)
22 (66.6)
0.2781
Underlying diseases
OSA (%)
2 (7.4)
2 (7.4)
0
0.7999
Cardiovascular disease (%)
29 (15.9)
23 (15.4)
6 (18.2)
0.6966
Respiratory disease (%)
9 (5.0)
6 (4.0)
3 (9.1)
0.4411
Renal disease (%)
7 (3.9)
6 (4.0)
1 (3.0)
0.8174
Vascular disease (%)
18 (10.0)
16 (10.7)
2 (6.1)
0.4154
ERCP: endoscopic retrograde cholangiopancreatography. Group A: control group consisting of patients with mild acute cholangitis or without acute cholangitis. Group B: group requiring emergent ERCP with severe or moderate acute cholangitis. ASA-PS classification: American Society of Anesthesiologists Physical Status classification. SD: standard deviation. OSA: obstructive sleep apnea.
